Biologics News

Patients with patellar tendinopathy who undergo ultrasound-guided leukocyte-rich platelet-rich plasma injections with dry needling and standardized eccentric exercises have faster short-term improvement compared with patients who undergo ultrasound-guided dry-needling alone, according to results of this study.

Platelet-rich plasma showed clinical superiority over cortisone for patients who received treatment for chronic hip bursitis, according to data presented at the American Academy of Orthopaedics Surgeons Annual Meeting.

Stem cell transplants was found to be viable and effective for halting or reversing degenerative disc disease in the spine, based on research conducted at the Mayo Clinic and presented at the American Academy of Pain Medicine Annual Meeting.

The results of a recently published study indicate that biological glenoid resurfacing can result in clinical failure in over half of all procedures.

It may not come as a surprise to learn that treatment of biofilm-related infections consume a massive part of the health care resources worldwide. In the United States, up to 500,000 primary blood stream infections occur annually among 150 million intravascular devices implanted. It is estimated that in 2014, more than $1 billion will be spent to treat periprosthetic joint infection of the hip and the knee.

The FDA issued 510(k) clearance to BioStructures LLC for its Signafuse bioactive one graft putty, which is indicated for the posterolateral spine, extremities and pelvis as well as a bone graft extender in the posterolateral spine.

Among patients with acute spinal cord injury, administration of granulocyte colony-stimulating factor had beneficial effects on neurological recovery, according to study results published in Spine.

Liventa Bioscience and Cryoport Inc. announced a major strategic alliance aimed at serving the many points of orthopedic care delivery with Liventa’s cell-based, advanced biologic tissue forms.

DePuy Synthes and DePuy Synthes Biomaterials, divisions of DePuy Orthopaedics Inc., have entered into an exclusive worldwide representative agreement for the marketing and promotion of a new cellular allograft product developed by LifeNet Health.

Results of a randomized, double-blind controlled study in the Journal of Bone and Joint Surgery supported the use of human mesenchymal stem cell for meniscal regeneration and the control of knee pain. “There was evidence of meniscus regeneration and improvement in knee pain following treatment with allogeneic human mesenchymal stem cells,” C. Thomas Vangsness Jr., MD, and colleagues wrote in the study. “These results support the study of human mesenchymal stem cells for the apparent knee-tissue regeneration and protective effects.” The study followed 55 patients at seven institutions who underwent partial medial meniscectomy and received the study treatment 7 days to 10 days after meniscectomy via a superolateral knee injection.